0

Familial Adenomatous Polyposis - A Pipeline Analysis Report

  • Published: Jul 2018
  • Pages: 59
  • SKU: IRTNTR23264
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for familial adenomatous polyposis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for familial adenomatous polyposis

Familial adenomatous polyposis (FAP) is an inherited disorder, which causes extra tissue formation in the colon or large intestine and later forms cancer in the colon. FAP is an inherited situation leading to the development of additional tissues known as polyps, in the large intestine. Polyps can also form in the upper gastrointestinal tract, especially in the upper part of the small intestine. If FAP is not treated in the early ages, it can become cancerous. The milder form of FAP is called attenuated familial adenomatous polyposis (AFAP), in which the growth of polyps is slow. The companies are forming strategic exclusive agreements or are acquiring other companies. For instance, companies including Tillotts Pharma and Sucampo Pharmaceuticals entered into exclusive licensing agreements with Cancer Prevention Pharmaceuticals, thereby helping Cancer Prevention Pharmaceuticals in developing and commercializing its drug candidate in Europe, Japan, and North America for the treatment of FAP. Consequently, the rising incidences of this condition is expected to promote the drug development for familial adenomatous polyposis.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for familial adenomatous polyposis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of familial adenomatous polyposis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

  • Cancer Prevention Pharmaceuticals
  • Marina Biotech
  • RMX Biopharma
  • Stem Synergy Therapeutics

Therapeutic assessment of the drug development pipeline for familial adenomatous polyposis by route of administration

  • Oral

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for familial adenomatous polyposis by therapy

  • Monotherapy
  • Combination therapy

According to this pipeline analysis report, most of the the molecules that are currently in the drug development pipeline for familial adenomatous are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

  • What are the drug molecules in the various development stages for familial adenomatous polyposis?
  • What are the companies that are currently involved in the development of drug molecules for familial adenomatous polyposis?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule

 

Technavio also offers customization on reports based on specific client requirement.

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>